ArticleInternational cancer conference journal2026
Mitomycin, 5-fluorouracil, and radiotherapy for anal canal cancer in a patient undergoing hemodialysis: a case report.
Article in International cancer conference journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anal cancer is a rare malignancy that accounts for only 0.3% of all cancer cases. Clinical data on treatment strategies for patients with special conditions, such as impaired renal function or those undergoing dialysis, are limited. Herein, we report a case highlighting the efficacy and safety of a combination regimen of mitomycin C (MMC), 5-fluorouracil (5-FU), and radiotherapy (RT) in a patient undergoing dialysis. A 65 year-old woman undergoing hemodialysis three times per week for chronic kidney disease associated with polycystic kidney disease presented with hematochezia. Biopsy confirmed human papillomavirus (HPV)-related anal squamous cell carcinoma, clinical stage cT1N0M0 (Stage I). The patient underwent two cycles of MMC and 5-FU combined with RT. The adverse events included grade 3 neutropenia, grade 3 thrombocytopenia, grade 2 nausea, grade 1 vomiting, and grade 3 diarrhea. Post-treatment endoscopic and histological evaluations confirmed a complete response. This case suggests that MMC + 5-FU + RT may be a viable treatment option with manageable toxicity, even in patients with anal canal cancer undergoing dialysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.